Uveitis in Giant Cell Arteritis: A Retrospective Study of Seven Observational Cases and Literature Review.

Giant cell arteritis elderly uveitis

Journal

Ocular immunology and inflammation
ISSN: 1744-5078
Titre abrégé: Ocul Immunol Inflamm
Pays: England
ID NLM: 9312169

Informations de publication

Date de publication:
10 Oct 2023
Historique:
medline: 10 10 2023
pubmed: 10 10 2023
entrez: 10 10 2023
Statut: aheadofprint

Résumé

To describe the demographic and clinical characteristics of uveitis in patients with giant cell arteritis (GCA), their treatments, and evolution. A national retrospective cohort study was performed. The inclusion criteria were as follows: patients with GCA fulfilling the 2022 ACR/EULAR criteria and a diagnostic of uveitis attested by an ophthalmologist. Seven women were included. The median age at diagnosis of uveitis was 71 years (64-84). All uveitis were diagnosed during active GCA (five at initial diagnosis, two at relapse). All uveitis were acute (100%), mostly anterior (86%) and bilateral (71%). Granulomatous features were less common (29%). All uveitis were treated with local and systemic corticosteroids. After a median follow-up of 30 (21-55) months, all patients achieved complete ophthalmic remission, with only one relapse at 2 years. GCA was also in complete remission. Uveitis could reveal GCA, and its presence correlated with disease activity of GCA. The most frequent clinical presentation of uveitis was acute and anterior; using local and systemic corticosteroids, the prognosis was favorable.

Identifiants

pubmed: 37815855
doi: 10.1080/09273948.2023.2264383
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-8

Auteurs

William Gil (W)

Department of Internal Medicine, Hôpital Universitaire Gabriel-Montpied, Clermont-Ferrand, France.
Université Clermont-Auvergne, Clermont-Ferrand, France.

Laurent Kodjikian (L)

Department of Ophthalmology, Hôpital Universitaire Croix-Rousse, Lyon, France.
UMR5510 MATEIS, CNRS, INSA Lyon, Lyon, France.

Marc Andre (M)

Department of Internal Medicine, Hôpital Universitaire Gabriel-Montpied, Clermont-Ferrand, France.
Université Clermont-Auvergne, Clermont-Ferrand, France.

Indeep Kaur (I)

University of Manchester, Manchester, UK.

Cécile Audrey Durel (CA)

Department of Internal Medicine, Hôpital Saint Joseph Saint Luc, Lyon, France.

Arnaud Hot (A)

UMR5510 MATEIS, CNRS, INSA Lyon, Lyon, France.
Department of Internal Medicine, Hôpital Universitaire Edouard Herriot, Lyon, France.

Maxime Fauter (M)

Department of Internal Medicine, Hôpital Universitaire Croix-Rousse, Lyon, France.

Benjamin Chaigne (B)

Department of Internal Medicine, Centre de Référence Maladies Auto-immunes Systémiques Rares d'Ile de France, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris Cité, Paris, France.

Perrine Smets (P)

Department of Internal Medicine, Hôpital Universitaire Gabriel-Montpied, Clermont-Ferrand, France.

Maxime Samson (M)

Department of Internal Medicine and Clinical Immunology, Hôpital Universitaire Dijon-Bourgogne, Dijon, France.

Pascal Seve (P)

Department of Internal Medicine, Hôpital Universitaire Croix-Rousse, Lyon, France.
Université Claude Bernard Lyon 1, Lyon, France.
Research on Healthcare Performance (RESHAPE), INSERM U1290, Université Claude Bernard Lyon 1, Lyon, France.

Classifications MeSH